Antibody profile in Indian severe haemophilia A patients with and without FVIII inhibitors

被引:1
|
作者
Pinto, Patricia [1 ]
Shetty, Shrimati [1 ]
Lacroix-Desmazes, Sebastien [2 ,3 ,4 ,5 ,6 ]
Bayry, Jagadeesh [2 ,3 ,4 ,5 ,6 ]
Kaveri, Srini [2 ,3 ,4 ,5 ,6 ]
Ghosh, Kanjaksha [1 ]
机构
[1] Natl Inst Immunohaematol ICMR, 13th Floor,New Multistoreyed Bldg,KEM Hosp Campus, Bombay 400012, Maharashtra, India
[2] Ctr Rech Cordeliers, INSERM, UMRS 1138, Paris, France
[3] Univ Paris 06, UMRS 1138, Paris, France
[4] Univ Paris 05, UMRS 1138, Paris, France
[5] Lab Int Assoc INSERM, Paris, France
[6] ICMR, Paris, France
关键词
Haemophilia A; FVIII; Inhibitors; Autoantibodies; India; FACTOR-VIII INHIBITORS; PREVIOUSLY UNTREATED PATIENTS; RECOMBINANT FACTOR-VIII; RISK-FACTORS; ACQUIRED HEMOPHILIA; LUPUS ANTICOAGULANT; FACTOR-IX; HEPATITIS-C; EFFICACY; MARKERS;
D O I
10.1016/j.imlet.2015.09.013
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Diagnosis and management of haemophilia patients with inhibitors is often tricky due to the heterogeneous nature of the antibodies with regard to their kinetics, as well as the co-existence of other interfering antibodies. Plasma samples from severe haemophilia A patients from India with and without FVIII inhibitors were analysed for the presence of possible co-existing antibodies such as lupus anticoagulants (LA), anti-cardiolipin antibodies (ACLA), anti-132-glycoprotein-I (anti-beta 2-GP-I) antibodies, viral transfusion transmitted disease (HIV, HBsAg, HCV) related antibodies, anti-cyclic citrullinated peptides (anti-CCP), and anti-nuclear antibodies. A high incidence of LA and anti-HCV antibodies was detected in Indian haemophilia A patients similar to earlier reports. More importantly, a relatively high incidence of autoantibodies to nuclear antigens (18.62%) and anti-CCP antibodies (1.38%) associated with autoimmune disorders was also seen in these congenital haemophilia A patients with and without inhibitors. Knowledge on the antibody profile in these haemophilia patients especially in those with FVIII inhibitors along with correlation with the clinical manifestations and other risk factors for inhibitor development could possibly shed more light on the complex immune response in these patients. (C) 2015 Elsevier B.V. All rights reserved.
引用
收藏
页码:93 / 97
页数:5
相关论文
共 50 条
  • [1] The Epidemiology of FVIII Inhibitors in Indian Haemophilia A Patients
    Patricia Pinto
    Tejashree Shelar
    Vidhya Nawadkar
    Darshana Mirgal
    Alfiya Mukaddam
    Preethi Nair
    Priyanka Kasatkar
    Tejasvita Gaikwad
    Shahnaz Ali
    Anshul Jadli
    Rucha Patil
    Anita Parihar
    Sharda Shanbhag
    Bipin Kulkarni
    Kanjaksha Ghosh
    Shrimati Shetty
    Indian Journal of Hematology and Blood Transfusion, 2014, 30 : 356 - 363
  • [2] The Epidemiology of FVIII Inhibitors in Indian Haemophilia A Patients
    Pinto, Patricia
    Shelar, Tejashree
    Nawadkar, Vidhya
    Mirgal, Darshana
    Mukaddam, Alfiya
    Nair, Preethi
    Kasatkar, Priyanka
    Gaikwad, Tejasvita
    Ali, Shahnaz
    Jadli, Anshul
    Patil, Rucha
    Parihar, Anita
    Shanbhag, Sharda
    Kulkarni, Bipin
    Ghosh, Kanjaksha
    Shetty, Shrimati
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2014, 30 (04) : 356 - 363
  • [3] A study of risk factors for the development of FVIII inhibitors in Indian severe haemophilia A patients
    Pinto, P.
    Ghosh, K.
    Shetty, S.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 1080 - 1080
  • [4] Prophylactic Treatment of Severe Haemophilia A Patients with Inhibitors to FVIII with Peglip-FVIII
    Timofeeva, Margarita
    Zozulya, Nadezhda I.
    Pospelova, Tatiana
    Kosinova, Marina V.
    Kurtov, Igor
    Tuddenham, Edward
    Ling, Gavin
    BLOOD, 2021, 138
  • [5] Prophylactic Treatment of Severe Haemophilia a Patients with Inhibitors to FVIII with Peglip-FVIII
    Tuddenham, Edward
    Wolf-Garraway, Richard
    Ling, Gavin
    BLOOD, 2022, 140 : 5617 - 5618
  • [6] Prevalence of FVIII inhibitors in severe haemophilia A patients: Effect of treatment and genetic factors in an Indian population
    David, Sachin
    Nair, Sukesh C.
    Singh, G. Surender
    Abu Alex, Ansu
    Ganesan, Saravanan
    Palani, Hamenth Kumar
    Balasundaram, Nithya
    Lakshmi, Kavitha M.
    Joshi, Aditi
    Kannan, S.
    Korula, Anu
    Aboobacker, Fouzia Nambiatheyil
    Abraham, Aby
    George, Biju
    Apte, Shashikant Janardan
    Srivastava, Alok
    Mathews, Vikram
    HAEMOPHILIA, 2019, 25 (01) : 67 - 74
  • [7] Cytokine profile and FVIII inhibitors development in haemophilia A
    Oliveira, C. A.
    Velloso-Rodrigues, C.
    Machado, F. C. J.
    Carvalho, B. N.
    Gentz, S. H. L.
    Martins-Filho, O. A.
    Chaves, D. G.
    HAEMOPHILIA, 2013, 19 (03) : E139 - E142
  • [8] IgG subclasses of FVIII inhibitors in severe haemophilia A patients: analysis by flow cytometry
    Irigoyen, M.
    Galassi, N.
    Bracco, M.
    Candela, M.
    Perez Bianco, R.
    Primiani, L.
    HAEMOPHILIA, 2010, 16 : 74 - 74
  • [9] How to treat patients with severe haemophilia A without FVIII concentrates? New concepts in haemophilia therapy (bi-specific antibody mimicking VIII)
    Shima, M.
    HAEMOPHILIA, 2015, 21 : 7 - 8
  • [10] Long-term analysis of real clinical practice of emicizumab treatment in patients with severe haemophilia A with and without FVIII inhibitors
    Zozulya, N.
    Dimitrieva, O.
    Yakovleva, E.
    HAEMOPHILIA, 2024, 30 : 122 - 122